SAN
DIEGO, Feb. 27, 2023 /PRNewswire/ -- NuVasive,
Inc. (NASDAQ: NUVA), the leader in spine technology innovation,
focused on transforming spine surgery with minimally disruptive,
procedurally integrated solutions, announced today that NuVasive
management will participate in upcoming investor conferences and
will be joined by Globus Medical management to discuss the two
companies' recent merger announcement and other business
topics:
- Citi 2023 Healthcare Services, MedTech, Tools and HCIT
Conference, March 2, 2023 in
New York City. The fireside chat
will begin at 9:30 a.m. ET.
- Cowen's 43rd Annual Health Care Conference,
March 8, 2023 in Boston. The fireside chat will begin at
2:10 p.m. ET.
- Barclays Global Healthcare Conference, March 14, 2023 in Miami. The fireside chat will begin at
10:45 a.m. ET.
Live webcasts of the presentations will be available on the
Investor Relations page of the Company's website
at www.nuvasive.com. After the live webcasts, replays of the
presentations will remain available on the website for 30
days.
About NuVasive
NuVasive,
Inc. (NASDAQ: NUVA) is the leader in spine technology
innovation, with a mission to transform surgery, advance care, and
change lives. The Company's less-invasive, procedurally integrated
surgical solutions are designed to deliver reproducible and
clinically proven outcomes. The Company's comprehensive procedural
portfolio includes surgical access instruments, spinal implants,
fixation systems, biologics, software for surgical planning,
navigation and imaging solutions, magnetically adjustable implant
systems for spine and orthopedics, and intraoperative
neuromonitoring technology and service offerings. With more
than $1 billion in net sales, NuVasive operates
in more than 50 countries serving surgeons, hospitals, and
patients. For more information, please
visit www.nuvasive.com.
Globus Medical and NuVasive Announcement
On
February 9, 2023, Globus Medical and
NuVasive announced a definitive agreement to combine the companies
in an all-stock transaction. The announcement can be found on the
Investor Relations section of our website.
No Offer or Solicitation
This news release is
for informational purposes only and is not intended to and does not
constitute an offer to subscribe for, buy or sell, or the
solicitation of an offer to subscribe for, buy or sell, or a
solicitation of any vote or approval in any jurisdiction, nor shall
there be any sale, issuance or transfer of securities in any
jurisdiction in which such offer, sale or solicitation would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. No offer of securities
shall be made except by means of a prospectus meeting the
requirements of Section 10 of the Securities Act of 1933, as
amended, and otherwise in accordance with applicable law.
Forward-Looking
Statements
NuVasive cautions you that statements
included in this news release that are not a description of
historical facts are forward-looking statements that involve risks,
uncertainties, assumptions and other factors which, if they do not
materialize or prove correct, could
cause NuVasive's results to differ materially from
historical results or those expressed or implied by such
forward-looking statements. The potential risks and uncertainties
which contribute to the uncertain nature of these statements
include, among others, risks associated with acceptance of the
Company's surgical products and procedures by spine surgeons and
hospitals, development and acceptance of new products or product
enhancements, clinical and statistical verification of the benefits
achieved via the use of NuVasive's products, the
Company's ability to adequately manage inventory as it continues to
release new products, its ability to recruit and retain management
and key personnel, and the other risks and uncertainties described
in NuVasive's news releases and periodic filings with
the Securities and Exchange
Commission. NuVasive's public filings with
the Securities and Exchange Commission are available
at www.sec.gov. NuVasive assumes no obligation to
update any forward-looking statement to reflect events or
circumstances arising after the date on which it was
made.
Important Information About the Transaction and Where To
Find It
In connection with the proposed transaction,
Globus Medical will file with the U.S. Securities and Exchange
Commission ("SEC") a registration statement on Form S-4 that will
include a joint proxy statement of Globus Medical and NuVasive and
that will also constitute a prospectus of Globus Medical for shares
of its class A common stock to be offered in the proposed
transaction. Globus Medical and NuVasive may also file other
documents with the SEC regarding the proposed transaction. This
document is not a substitute for the joint proxy statement
statement/prospectus or registration statement or any other
document which Globus Medical or NuVasive may file with the SEC.
INVESTORS AND SECURITY HOLDERS OF GLOBUS MEDICAL AND NUVASIVE ARE
URGED TO READ THE REGISTRATION STATEMENT, WHICH WILL INCLUDE THE
JOINT PROXY STATEMENT/PROSPECTUS, AND ANY OTHER RELEVANT DOCUMENTS
THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY
AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN
THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT
INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. The
registration statement, definitive joint proxy statement/prospectus
and other documents filed by Globus Medical and NuVasive with the
SEC will be available free of charge at the SEC's website
(www.sec.gov) and from Globus Medical and NuVasive. Requests for
copies of the joint proxy statement/ prospectus and other documents
filed by Globus Medical with the SEC may be made by contacting
Keith Pfeil, Chief Financial Officer
by phone at (610) 930-1800 or by email at kpfeil@globusmedical.com,
and request for copies of the joint proxy statement/prospectus and
other documents filed by NuVasive may be made by contacting
Matt Harbaugh, Chief Financial
Officer, by phone at (858) 210-2129 or by email at
investorrelations@nuvasive.com.
Participants in the Solicitation
Globus
Medical, NuVasive, their respective directors and certain of their
executive officers and other employees may be deemed to be
participants in the solicitation of proxies from Globus Medical's
and NuVasive's shareholders in connection with the proposed
transaction. Information about the directors and executive officers
of Globus Medical and their ownership of Globus Medical stock is
set forth in Globus Medical's annual report on Form 10-K for the
fiscal year ended December 31, 2022,
which was filed with the SEC on February 21,
2023 and its proxy statement for its 2022 annual meeting of
stockholders, which was filed with the SEC on April 21, 2022. Information regarding NuVasive's
directors and executive officers is contained in NuVasive's annual
report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC
on February 22, 2023, and its proxy
statement for its 2022 annual meeting of stockholders, which was
filed with the SEC on March 30, 2022.
Certain directors and executive officers of Globus Medical and
NuVasive may have a direct or indirect interest in the transaction
due to securities holdings, vesting of equity awards and rights to
severance payments. Additional information regarding the persons
who may, under the rules of the SEC, be deemed participants in the
solicitation of Globus Medical's and NuVasive's shareholders in
connection with the proposed transaction will be included in the
joint proxy statement/prospectus. These documents can be obtained
free of charge from the sources indicated above.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nuvasive-to-participate-in-upcoming-investor-conferences-301757078.html
SOURCE NuVasive, Inc.